Clinical Trials Logo

Clinical Trial Summary

Fluid therapy is often used as first line treatment of acute circulatory failure, aiming an increase in cardiac output (by improving preload) and in tissue perfusion. Depending on left ventricular systolic function, fluid challenge could lead to an increase in cardiac ouput and tissue perfusion, or only detrimental consequences (by fluid overload and aggravation of lung and tissues oedema, increase of morbi-mortality). Patients are defined as responders to fluid therapy if one can observe an increase of cardiac output up to 15% after fluid therapy (500ml of crystalloids): gold standard test used in most of the studies on the subject. Literature reports on heterogenous populations a reproductible and constant response rate to this fluid challenge of 50%. It seems reasonable to dispose of indices allowing to predict fluid responsiveness without resulting in fluid intake. Statics markers have been abandonned for several years and dynamics methods have been developped.

In front of arrythmia, validated methods are scarce. Passive leg rising method appears to be the only one and it's validity seems to be less well documented than in sinusal patients. The purpose of this study is to determine a new method to assess fluid responsiveness in arrythmic patients.

In atrial fibrillation, RR interval varies widely between cardiac cylces. Systolic interval remain constant. Variations will occure at expense of diastolic interval, or ventricular filling interval. One can reliably assume that when RR is longer, preload is rising. If the patient is on the ascendant part of the Franck-Starling curve, a longer RR should cause au greater VTI (Vitess Time Integral, surrogate of cardiac output).

The evaluation by transthoracic echocardiography of the indice delta ITV / delta RR should determine the degree of fluid responsiveness in arrhythmic patients.

After decision of fluid expansion, patients will have haemodynamic and echocardiographic data measured, delta ITV / delta RR indice assessed, then passive leg rising and fluid expansion with 500 ml of cristalloids administered, with evaluation of VTI (as surrogate of cardiac output) at each time. Fluid responders will be compared to non-responders to evaluate the diagnostic performances of the indice delta ITV / delta RR.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03461094
Study type Interventional
Source Poitiers University Hospital
Contact
Status Completed
Phase N/A
Start date May 17, 2017
Completion date June 12, 2020

See also
  Status Clinical Trial Phase
Completed NCT02949180 - Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation N/A
Completed NCT03188484 - Atrial Fibrillation Research In CATalonia
Completed NCT05295056 - Clinical Performance of the AFGen1 Device Over a 7-day Period
Completed NCT03507335 - Atrial Fibrillation Detection: 24 Hour Study
Recruiting NCT06299514 - RAFT-P&A Randomized Control Trial N/A